CANOPY Growth is primed to cull a host of existing brands as it looks to build a multi-market, seed-to-patient model and distance itself from a ‘false starts’ legacy, says CEO Luc Mongeau.
Thursday’s cannabis news is shaped by the contested aftermath of the Justice Department’s April rescheduling of medical cannabis to Schedule III.
Wednesday brings a landmark for cannabis capital markets, with Trulieve set to become the first US plant-touching operator to open trading on the New York Stock Exchange and Verano preparing its own exchange push via a reverse stock split.
Virginia’s retail cannabis market moved closer on Monday, with Governor Abigail Spanberger and legislative sponsors describing budget negotiations as “incredible and productive” ahead of the June 30 special session deadline.
The week opens with a landmark moment for cannabis capital markets as Trulieve prepares to become the first US cannabis company to list on a major American exchange.
Thursday marked the end of a five-year wait for Alabama: its first licensed medical cannabis dispensary began trading, a milestone that arrived alongside intensifying opposition to the federal rescheduling order.
A run of legislative action across the United States and Australia is broadening medical cannabis access, while a new peer-reviewed study adds clinical weight to one of the plant’s therapeutic applications.
Tuesday’s cannabis headlines ranged from Capitol Hill to Berlin.
The legal soundness of the United States’ cannabis rescheduling process came under renewed scrutiny on Sunday as fresh analysis argued that the post-Chevron regulatory landscape may expose the DEA’s scheduling procedures to constitutional challenge.
